Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Classification of Rhabdomyosarcoma and Its Molecular Basis

Parham, David M. MD; Barr, Frederic G. MD, PhD

doi: 10.1097/PAP.0b013e3182a92d0d
Review Articles

Rhabdomyosarcoma (RMS), the most common soft tissue sarcoma in children, has traditionally been classified into embryonal rhabdomyosarcoma (ERMS) and alveolar rhabdomyosarcoma (ARMS) for pediatric oncology practice. This review outlines the historical development of classification of childhood RMS and the challenges that have been associated with it, particularly problems with the diagnosis of “solid variant” ARMS and its distinction from ERMS. In addition to differences in clinical presentation and outcome, a number of genetic features underpin separation of ERMS from ARMS. Genetic differences associated with RMS subclassification include the presence of reciprocal translocations and their associated fusions in ARMS, amplification of genes in ARMS and its fusion subsets, chromosomal losses and gains that mostly occur in ERMS, and allelic losses and mutations usually associated with ERMS. Chimeric proteins encoded in most ARMS from the fusion of PAX3 or PAX7 with FOXO1 are expressed, result in a distinct pattern of downstream protein expression, and appear to be the proximate cause of the bad outcome associated with this subtype. A sizeable minority of ARMS lacks these fusions and shares the clinical and biological features of ERMS. A battery of immunohistochemical tests may prove useful in separating ERMS from ARMS and fusion-positive ARMS from fusion-negative ARMS. Because of limitation of predicting outcome solely based on histologic classification, treatment protocols will begin to utilize fusion testing for stratification of affected patients into low-risk, intermediate-risk, and high-risk groups.

*Department of Pathology, University of Oklahoma Health Science Center, Oklahoma City, OK

Laboratory of Pathology, National Cancer Institute, Bethesda, MD

F.G.B. was supported by Intramural Program of the National Cancer Institute.

D.M.P. receives salary support from the Children’s Oncology Group, derived from National Cancer Institute grant U10 CA98543. The other author has no conflicts of interest to disclose.

Reprints: David M. Parham, MD, Department of Pathology, University of Oklahoma Health Science Center, 940 Stanton L. Young Blvd., BMSB451, Oklahoma City, OK 73104 (e-mail:

Copyright © 2013 Wolters Kluwer Health, Inc. All rights reserved.